(EWTX) Edgewise Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 3.395m USD | Total Return: 64.6% in 12m

Stock Muscle Therapies, Cardiac Therapies, Genetic Disorders
Total Rating 50
Risk 80
Buy Signal 0.67
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 3,395m
Avg Trading Vol: 26.9M USD
ATR: 5.19%
Peers RS (IBD): 77.8
Risk 5d forecast
Volatility80.5%
Rel. Tail Risk-18.4%
Reward TTM
Sharpe Ratio0.79
Alpha8.74
Character TTM
Beta1.583
Beta Downside0.316
Drawdowns 3y
Max DD68.81%
CAGR/Max DD1.05
EPS (Earnings per Share) EPS (Earnings per Share) of EWTX over the last years for every Quarter: "2021-03": -4.37, "2021-06": -0.21, "2021-09": -0.26, "2021-12": -0.26, "2022-03": -0.3, "2022-06": -0.32, "2022-09": -0.34, "2022-12": -0.31, "2023-03": -0.36, "2023-06": -0.34, "2023-09": -0.41, "2023-12": -0.47, "2024-03": -0.33, "2024-06": -0.34, "2024-09": -0.36, "2024-12": -0.42, "2025-03": -0.43, "2025-06": -0.34, "2025-09": -0.39, "2025-12": -0.47, "2026-03": 0,
EPS CAGR: 30.71%
EPS Trend: 14.6%
Last SUE: 4.00
Qual. Beats: 1
Revenue Revenue of EWTX over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 2.252, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 2.118, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0, 2026-03: null,
Rev. CAGR: 0.00%
Rev. Trend: 12.0%
Last SUE: 0.00
Qual. Beats: 0
Risks
Technicals: volatile
Description: EWTX Edgewise Therapeutics

Edgewise Therapeutics, Inc. (EWTX) is a biotechnology company focused on developing treatments for muscle disorders.

Its primary drug candidate, sevasemten, is in Phase II clinical trials for Duchenne and Becker muscular dystrophies. These are genetic conditions characterized by progressive muscle degeneration.

EWTX also has EDG-7500 in Phase I for hypertrophic cardiomyopathy and EDG-15400 for heart failure with preserved ejection fraction. The companys pipeline includes additional precision medicine candidates targeting various genetically defined muscle disorders, a common approach in modern drug discovery.

Further analysis of EWTXs pipeline and market potential is available on ValueRay.

Headlines to Watch Out For
  • Sevasemten clinical trial results impact stock
  • Regulatory approval for muscle disorder therapies crucial
  • Competition in muscular dystrophy market affects outlook
  • Early-stage pipeline development influences valuation
Piotroski VR‑10 (Strict, 0-10) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.26 > 0.02 and ΔFCF/TA -3.36 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.26 > 3% & CFO -143.8m > Net Income -167.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 19.85 > 1.5 & < 3
Outstanding Shares: last quarter (102.9m) vs 12m ago 11.38% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.44%; Δ -0.44% > 0%)
Interest Coverage Ratio: -15.40 > 6 (EBITDA TTM -179.5m / Interest Expense TTM -11.7m)
Altman Z'' -15.00
A: 0.93 (Total Current Assets 543.4m - Total Current Liabilities 27.4m) / Total Assets 552.6m
B: -0.99 (Retained Earnings -546.4m / Total Assets 552.6m)
C: -0.35 (EBIT TTM -179.5m / Avg Total Assets 519.7m)
D: -17.98 (Book Value of Equity -545.7m / Total Liabilities 30.3m)
Altman-Z'' Score: -18.30 = D
Beneish M
DSRI: none (Receivables none/none, Revenue 0.0/2.12m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.0 (AQ_t 0.0 / AQ_t-1 0.00)
SGI: none (Revenue 0.0 / 2.12m)
TATA: -0.04 (NI -167.8m - CFO -143.8m) / TA 552.6m)
Beneish M-Score: cannot calculate (missing components)
What is the price of EWTX shares? As of April 02, 2026, the stock is trading at USD 31.50 with a total of 1,063,594 shares traded.
Over the past week, the price has changed by +3.76%, over one month by +11.58%, over three months by +39.54% and over the past year by +64.63%.
Is EWTX a buy, sell or hold? Edgewise Therapeutics has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy EWTX.
  • StrongBuy: 5
  • Buy: 3
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the EWTX price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 41.1 30.4%
Analysts Target Price 41.1 30.4%
EWTX Fundamental Data Overview as of 02 April 2026
P/B = 5.9648
Revenue TTM = 0.0 USD
EBIT TTM = -179.5m USD
EBITDA TTM = -179.5m USD
Long Term Debt = 3.99m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.01m USD (from shortTermDebt, last quarter)
Debt = 3.99m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -57.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.87b USD (3.40b + Debt 3.99m - CCE 530.1m)
Interest Coverage Ratio = -15.40 (Ebit TTM -179.5m / Interest Expense TTM -11.7m)
EV/FCF = -19.95x (Enterprise Value 2.87b / FCF TTM -143.8m)
FCF Yield = -5.01% (FCF TTM -143.8m / Enterprise Value 2.87b)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.12m) / Revenue TTM)
 Tobins Q-Ratio = 5.19 (Enterprise Value 2.87b / Total Assets 552.6m)
 Interest Expense / Debt = 77.87% (Interest Expense 3.11m / Debt 3.99m)
 Taxrate = 21.0% (US default 21%)
NOPAT = -141.8m (EBIT -179.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 19.85 (Total Current Assets 543.4m / Total Current Liabilities 27.4m)
Debt / Equity = 0.01 (Debt 3.99m / totalStockholderEquity, last quarter 522.3m)
 Debt / EBITDA = 0.32 (negative EBITDA) (Net Debt -57.2m / EBITDA -179.5m)
 Debt / FCF = 0.40 (negative FCF - burning cash) (Net Debt -57.2m / FCF TTM -143.8m)
 Total Stockholder Equity = 524.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.29% (Net Income -167.8m / Total Assets 552.6m)
RoE = -31.97% (Net Income TTM -167.8m / Total Stockholder Equity 524.9m)
RoCE = -33.93% (EBIT -179.5m / Capital Employed (Equity 524.9m + L.T.Debt 3.99m))
 RoIC = -27.01% (negative operating profit) (NOPAT -141.8m / Invested Capital 524.9m)
 WACC = 11.54% (E(3.40b)/V(3.40b) * Re(11.55%) + (debt cost/tax rate unavailable))
Discount Rate = 11.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 26.06%
 [DCF] Fair Price = unknown (Cash Flow -143.8m)
 EPS Correlation: 14.62 | EPS CAGR: 30.71% | SUE: 4.0 | # QB: 1
Revenue Correlation: 12.00 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.49 | Chg7d=+0.000 | Chg30d=-0.039 | Revisions Net=-3 | Analysts=10
EPS current Year (2026-12-31): EPS=-2.07 | Chg7d=+0.000 | Chg30d=-0.112 | Revisions Net=-5 | Growth EPS=-26.9% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-2.34 | Chg7d=+0.000 | Chg30d=-0.260 | Revisions Net=-4 | Growth EPS=-13.1% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: -0.60 (1 Up / 4 Down within 30d for Next Quarter)
Additional Sources for EWTX Stock Fund Manager Positions: Dataroma · Stockcircle